Evofem Biosciences Files 8-K: Material Agreement & Equity Sales
Ticker: EVFM · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1618835
| Field | Detail |
|---|---|
| Company | Evofem Biosciences, Inc. (EVFM) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: EVFM
TL;DR
EVFM entered a material agreement and sold equity on 6/26, filed 7/2.
AI Summary
Evofem Biosciences, Inc. announced on June 26, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on July 2, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can signal significant business changes or financing activities that carry inherent risks.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- July 2, 2025 (date) — Date of report filing
- Delaware (jurisdiction) — State of incorporation
- 20-8527075 (id) — Commission File Number
- 7770 Regents Road , Suite 113-618 San Diego , California 92122 (address) — Principal executive offices
- (858) 550-1900 (phone) — Registrant's telephone number
FAQ
What type of material definitive agreement did Evofem Biosciences enter into?
The filing states that Evofem Biosciences, Inc. entered into a 'Material Definitive Agreement' on June 26, 2025, but the specific details of the agreement are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 26, 2025.
What is the principal executive office address for Evofem Biosciences, Inc.?
The principal executive offices of Evofem Biosciences, Inc. are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What is the Commission File Number for Evofem Biosciences, Inc.?
The Commission File Number for Evofem Biosciences, Inc. is 001-36754.
What other items are reported in this 8-K filing besides the material agreement?
In addition to the entry into a material definitive agreement, this 8-K filing also reports on Unregistered Sales of Equity Securities and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Evofem Biosciences, Inc. (EVFM).